Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000921 · ClinicalTrials.gov registry record · Phase 2

The Effects of Prednisone on HIV Levels and the Immune System

A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 2
Development phase
118
Enrollment target
18
Study locations

NCT00000921 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 118 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (74% lower). The trial reports 18 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000921, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 2
Development phase
118 participants
Enrollment target
18
Study locations

Study Summary

The purpose of this study is to see if it is safe and effective to give prednisone to HIV-infected patients. Prednisone is a corticosteroid, a hormone produced by the body that inhibits immune cell responses. Prednisone may be able to lower the level of HIV in the body (viral load) by reducing the number of cells that HIV can infect. At the same time, prednisone may be able to increase CD4 cell counts (cells of the immune system that fight infection).

Conditions Studied

HIV Infections

Interventions

  • DRUG Prednisone

Study Locations (18)

Hawaii

  • Queens Med Ctr - Honolulu
  • Univ of Hawaii / Leahi Hosp - Honolulu
  • Univ of Hawaii - Honolulu

Illinois

  • Northwestern Univ Med School - Chicago
  • Cook County Hosp - Chicago
  • Rush Presbyterian - Saint Luke's Med Ctr - Chicago

Ohio

  • Case Western Reserve Univ - Cleveland
  • MetroHealth Med Ctr - Cleveland
  • Ohio State Univ Hosp Clinic - Columbus

New York

  • Bellevue Hosp / New York Univ Med Ctr - New York
  • Mount Sinai Med Ctr - New York

Alabama

  • Univ of Alabama at Birmingham - Birmingham

California

  • Univ of Southern California / LA County USC Med Ctr - Los Angeles

Indiana

  • Indiana Univ Hosp - Indianapolis

Massachusetts

  • Harvard (Massachusetts Gen Hosp) - Boston

Trial Details

FieldValue
Enrollment Target 118 participants
Start Date 1996-08
Phase Phase 2

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00000921

The ClinicalTrials.gov registry entry for NCT00000921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (74% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Prednisone is the first listed.

NCT00000921 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Hawaii, Illinois, Ohio.

Frequently Asked Questions

What is clinical trial NCT00000921 about?

NCT00000921 is a clinical study titled "The Effects of Prednisone on HIV Levels and the Immune System". The purpose of this study is to see if it is safe and effective to give prednisone to HIV-infected patients. Prednisone is a corticosteroid, a hormone produced by the body that inhibits immune cell responses. Prednisone may be able to lower the level of HIV in the body (viral load) by reducing the ...

What is the current status of trial NCT00000921?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 1996-08.

What conditions does trial NCT00000921 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000921?

The interventions under investigation include: Prednisone (DRUG).

Who is sponsoring clinical trial NCT00000921?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000921 being conducted?

This trial has 18 study locations across Alabama, California, Hawaii, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.